Primary source: The Ministerial Reliance Order: About the Order - Canada.ca
Health Canada established a legal framework that allows reliance on foreign regulatory assessments for designated drug classes, making safety and efficacy requirements contingent on verified foreign data.
This Order enhances efficiency in drug approvals in Canada, encourages more submissions, and fosters collaboration with international regulatory bodies, potentially increasing drug availability in the Canadian market.
Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Outlines scenarios for reliance: general deeming, 120-day filing, and joint reviews. Specifies requirements for demonstrating safety comparability.
Details the process for using foreign Risk Management Plans (RMPs) and safety data to satisfy Canadian requirements, provided the MAH justifies the applicability of foreign data to the Canadian context.
Potential to simplify submissions by removing the need for certain examinations.
Inclusion of reliance on foreign regulatory authority documents.
Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.
The Ministerial Reliance Order, effective July 15, 2026, permits Health Canada to accept certain drug submissions based on decisions or documents from foreign regulatory authorities. This aims to streamline the review process for new drug submissions (NDS), abbreviated NDS (ANDS), supplements to NDS (SNDS), and supplements to ANDS (SANDS) while ensuring drug safety and efficacy standards are met.
What changed: Health Canada established a legal framework that allows reliance on foreign regulatory assessments for designated drug classes, making safety and efficacy requirements contingent on verified foreign data.
Why it matters: This Order enhances efficiency in drug approvals in Canada, encourages more submissions, and fosters collaboration with international regulatory bodies, potentially increasing drug availability in the Canadian market.
Practical implication: Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.
Published from the Firecrawl policy change extraction pipeline.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
